Related Experiment Video
Updated: Jun 23, 2026

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
Nitric oxide synthase gene therapy: progress and prospects
Deirdre M O'Connor1, Timothy O'Brien
1REMEDI, NCBES, National University of Ireland, University Road, Galway, Ireland.
Abstract:
NOS gene therapy has been the focus of extensive research as dysfunction of this enzyme has been implicated in several cardiovascular diseases. Research has concentrated on comparing the effect of gene delivery of NOS isoforms (eNOS, iNOS and nNOS) in healthy and diseased animal models on intimal hyperplasia, restenosis, vascular tone and ischemia-reperfusion injury. Most results demonstrate therapeutic benefits following vascular gene delivery of all NOS in pre-clinical models of cardiovascular disease. eNOS has been shown to have particular promise as it promotes re-endothelialisation and inhibits intimal hyperplasia in injured blood vessels. The ultimate goal is to translate the benefit of NOS gene therapy in animal models into clinical practise. To develop NOS gene therapy for clinical use further work needs to be undertaken to improve delivery systems and vectors to minimise detrimental side-effects and enhance positive treatment outcomes. This review focuses on current research on NOS gene therapy in cardiovascular disease and identifies the next steps that would be necessary to lead to clinical trials.
Insights
Nitric oxide synthase (NOS) gene therapy shows promise for cardiovascular diseases by improving vascular function in preclinical models. Further research into delivery systems is needed for clinical application.
Area of Science:
- Cardiovascular Research
- Gene Therapy
- Enzyme Function
Background:
- Nitric oxide synthase (NOS) enzyme dysfunction is linked to cardiovascular diseases.
- NOS gene therapy is being investigated for therapeutic potential.
Purpose of the Study:
- To review current research on NOS gene therapy for cardiovascular diseases.
- To identify necessary steps for clinical translation.
Main Methods:
- Comparison of NOS isoforms (eNOS, iNOS, nNOS) gene delivery.
- Studies in healthy and diseased animal models.
- Evaluation of effects on intimal hyperplasia, restenosis, vascular tone, and ischemia-reperfusion injury.
Main Results:
- Vascular gene delivery of all NOS isoforms demonstrated therapeutic benefits in preclinical cardiovascular models.
- eNOS showed particular promise, promoting re-endothelialization and inhibiting intimal hyperplasia.
- Positive outcomes were observed in various cardiovascular conditions.
Conclusions:
- NOS gene therapy holds significant therapeutic potential for cardiovascular diseases.
- Further development of delivery systems and vectors is crucial for clinical translation.
- Minimizing side effects and enhancing treatment outcomes are key next steps for clinical trials.
More Related Videos
08:23Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
12:30Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
Related Concept Videos
Nitric Oxide Signaling Pathway
Gene Therapy
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Microorganisms in Medicine and Therapeutics